Medtronic (MDT) Earnings Date & Reports

Key Takeaways

• Fourth-quarter revenue reached $9.807 billion, up 9.9% reported and 6.6% organic, exceeding implied guidance by 90 basis points.
• Full-year fiscal 2026 revenue totaled $36.364 billion, rising 8.4% reported and 5.8% organic—the highest annual organic growth in 10 years.
• Q4 GAAP diluted EPS was $0.96 and non-GAAP diluted EPS was $1.55; full-year GAAP diluted EPS was $3.73 and non-GAAP diluted EPS was $5.53.
• Cardiovascular portfolio led growth with 13.8% reported and 10.1% organic increases in the quarter.
• Company raised its quarterly dividend to $0.72 per share, marking the 49th consecutive annual increase.
• FY2027 guidance calls for organic revenue growth of 6.75% to 7.25% and non-GAAP EPS of $5.90 to $6.00.

Earnings Context and Why It Matters

Medtronic’s fiscal year ends in late April, making the fourth quarter and full-year results a key checkpoint for investors tracking the medical device leader’s recovery and growth trajectory. After navigating pandemic-related disruptions and portfolio adjustments in prior years, the company has focused on high-growth areas such as cardiac ablation, diabetes, and surgical robotics. Strong performance in these segments can signal sustained momentum heading into fiscal 2027, while margin trends and cash generation provide insight into operational discipline amid evolving industry dynamics like tariffs and regulatory approvals.

Reported Results

Medtronic reported fourth-quarter worldwide revenue of $9.807 billion, an increase of 9.9% as reported and 6.6% on an organic basis. GAAP diluted EPS reached $0.96, while non-GAAP diluted EPS was $1.55. For the full fiscal year 2026, revenue totaled $36.364 billion, up 8.4% reported and 5.8% organic. GAAP diluted EPS was $3.73 and non-GAAP diluted EPS was $5.53. The company also provided fiscal 2027 guidance of 6.75% to 7.25% organic revenue growth and non-GAAP EPS in the range of $5.90 to $6.00. Results exceeded expectations on both revenue and EPS in the quarter, with notable strength in Cardiac Ablation Solutions and the Cardiovascular portfolio.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights on names like Medtronic may find the platform a useful complement to traditional research.

Market Reaction and Investor Sentiment

Shares of Medtronic traded higher in the immediate aftermath of the June 3 release, reflecting investor approval of the beat on both revenue and earnings as well as the constructive fiscal 2027 outlook. The announcement of another dividend increase further supported sentiment, underscoring management’s confidence in cash-flow generation. Broader market focus on healthcare technology innovation and Medtronic’s pipeline progress in areas such as Hugo robotic-assisted surgery likely contributed to the positive reception.

Forward Outlook and Key Factors to Monitor

Medtronic enters fiscal 2027 with guidance that incorporates the benefit of a 53rd week and full-year consolidation of the Diabetes business. Investors will track execution on the company’s robust pipeline, including regulatory milestones for Hugo RAS in additional indications and continued adoption of therapies such as Affera and Symplicity.

Portfolio momentum in Cardiac Rhythm Management and Acute Care & Monitoring remains important, as does the integration of recent tuck-in acquisitions. Margin performance will be watched closely given the noted impacts from tariffs and one-time items in the prior year.

Cash-flow generation and capital allocation, including the ongoing dividend program and potential further M&A, are additional areas of focus. Broader industry conditions such as hospital capital spending and reimbursement trends could influence demand across Medtronic’s diversified segments.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations